Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
Status:
Active, not recruiting
Trial end date:
2025-09-25
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the percentage of patients with Duration of
Severe Neutropenia (DSN) =0 in patients treated with:
Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel,
doxorubicin, and cyclophosphamide (TAC) + combination plinabulin/pegfilgrastim
Severe neutropenia is an absolute neutrophil count (ANC) <0.5 × 10^9/L.
Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this
study.